Published in Int J Cancer on November 20, 2004
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine (2006) 4.08
Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) (2011) 3.33
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Liposome: classification, preparation, and applications. Nanoscale Res Lett (2013) 1.41
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther (2011) 1.15
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol (2014) 1.05
Phosphorescent nanoscale coordination polymers as contrast agents for optical imaging. Angew Chem Int Ed Engl (2011) 1.04
Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered release. Angew Chem Int Ed Engl (2011) 1.04
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency. Nanomedicine (2010) 1.00
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials (2013) 0.99
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J Control Release (2013) 0.97
Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Antifolates to Cancer Cells. Chem Sci (2012) 0.96
The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials (2012) 0.94
Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release (2014) 0.92
Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano (2014) 0.91
Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials (2013) 0.90
The smart targeting of nanoparticles. Curr Pharm Des (2013) 0.89
Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem (2012) 0.84
A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. J Control Release (2015) 0.84
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J Control Release (2015) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Ligation strategies for targeting liposomal nanocarriers. Biomed Res Int (2014) 0.83
Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release (2013) 0.81
Self-assembled lipid nanomedicines for siRNA tumor targeting. J Biomed Nanotechnol (2009) 0.80
Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. Int J Nanomedicine (2012) 0.80
Cytotoxicity of naphthoquinones and their capacity to generate reactive oxygen species is quenched when conjugated with gold nanoparticles. Int J Nanomedicine (2011) 0.80
PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat Commun (2016) 0.79
Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy. Biomaterials (2014) 0.78
Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy. Theranostics (2017) 0.78
Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment. Mol Ther (2015) 0.78
A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting. Int J Nanomedicine (2015) 0.77
A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials (2016) 0.77
Exploring the tumor microenvironment with nanoparticles. Cancer Treat Res (2015) 0.77
Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Control Release (2016) 0.77
Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition. Mol Ther (2017) 0.77
Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate. J Control Release (2013) 0.76
The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. ACS Nano (2016) 0.76
Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity. Sci Rep (2015) 0.76
Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model. Mol Pharm (2013) 0.76
A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo. Mol Ther Nucleic Acids (2016) 0.75
A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study. Radiat Oncol (2017) 0.75
Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. ACS Appl Mater Interfaces (2016) 0.75
Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy. Biomaterials (2017) 0.75
Genome sequence of Aedes aegypti, a major arbovirus vector. Science (2007) 9.19
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Activation of Rac1 by shear stress in endothelial cells mediates both cytoskeletal reorganization and effects on gene expression. EMBO J (2002) 2.46
Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology (2007) 2.43
Anisotropic mechanosensing by mesenchymal stem cells. Proc Natl Acad Sci U S A (2006) 2.43
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol (2011) 2.19
Boolean network simulations for life scientists. Source Code Biol Med (2008) 2.05
Differential effects of equiaxial and uniaxial strain on mesenchymal stem cells. Biotechnol Bioeng (2004) 2.05
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer (2009) 2.01
Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci U S A (2007) 2.01
Myotube assembly on nanofibrous and micropatterned polymers. Nano Lett (2006) 2.00
Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation. J Biol Chem (2004) 1.96
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta (2009) 1.94
The effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-β. Biomaterials (2011) 1.93
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Bioactive nanofibers: synergistic effects of nanotopography and chemical signaling on cell guidance. Nano Lett (2007) 1.81
Rho mediates the shear-enhancement of endothelial cell migration and traction force generation. Biophys J (2004) 1.77
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Transforming growth factor-beta and notch signaling mediate stem cell differentiation into smooth muscle cells. Stem Cells (2010) 1.74
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat Commun (2012) 1.66
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release (2010) 1.64
Regulation of vascular smooth muscle cells by micropatterning. Biochem Biophys Res Commun (2003) 1.63
Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder. J Physiol (2015) 1.59
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Biophysical regulation of epigenetic state and cell reprogramming. Nat Mater (2013) 1.55
Non-viral is superior to viral gene delivery. J Control Release (2007) 1.54
Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun (2005) 1.50
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol (2006) 1.48
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci (2006) 1.46
Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng (2006) 1.46
PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci U S A (2004) 1.42
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Arsenic-stimulated liver sinusoidal capillarization in mice requires NADPH oxidase-generated superoxide. J Clin Invest (2008) 1.33
Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv (2005) 1.32
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int (2009) 1.28
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem (2010) 1.28
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.25
Differential regulation of Rho GTPases by beta1 and beta3 integrins: the role of an extracellular domain of integrin in intracellular signaling. J Cell Sci (2002) 1.24
Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol (2007) 1.24
Boolean modeling of transcriptome data reveals novel modes of heterotrimeric G-protein action. Mol Syst Biol (2010) 1.23
A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano (2013) 1.22
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
Development of non-viral vectors for systemic gene delivery. J Control Release (2002) 1.21
Common and unique elements of the ABA-regulated transcriptome of Arabidopsis guard cells. BMC Genomics (2011) 1.21
Extremely high prevalence of neural tube defects in a 4-county area in Shanxi Province, China. Birth Defects Res A Clin Mol Teratol (2006) 1.21
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Role of cell surface heparan sulfate proteoglycans in endothelial cell migration and mechanotransduction. J Cell Physiol (2005) 1.20
Synthesis of a series of novel 2,4,5-trisubstituted selenazole compounds as potential PLTP inhibitors. Bioorg Med Chem Lett (2010) 1.20
Biomimetic collagen scaffolds for human bone cell growth and differentiation. Tissue Eng (2004) 1.19
Cell-shape regulation of smooth muscle cell proliferation. Biophys J (2009) 1.19
Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther (2005) 1.19
miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol (2012) 1.19
Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice. Hepatology (2005) 1.17
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther (2010) 1.17
Inhibition of Pkhd1 impairs tubulomorphogenesis of cultured IMCD cells. Mol Biol Cell (2005) 1.17
Interplay between integrins and FLK-1 in shear stress-induced signaling. Am J Physiol Cell Physiol (2002) 1.17
A rodent model of myocardial infarction for testing the efficacy of cells and polymers for myocardial reconstruction. Nat Protoc (2006) 1.16
Beclin 1-independent autophagy induced by a Bcl-XL/Bcl-2 targeting compound, Z18. Autophagy (2010) 1.15
Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther (2011) 1.15
Biophysical regulation of histone acetylation in mesenchymal stem cells. Biophys J (2011) 1.14
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat (2006) 1.14
An ana2/ctp/mud complex regulates spindle orientation in Drosophila neuroblasts. Dev Cell (2011) 1.13
Regulation of vascular smooth muscle cells and mesenchymal stem cells by mechanical strain. Mol Cell Biomech (2006) 1.13
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res (2005) 1.12
Antithrombogenic modification of small-diameter microfibrous vascular grafts. Arterioscler Thromb Vasc Biol (2010) 1.12
Molecular basis of mechanical modulation of endothelial cell migration. Front Biosci (2005) 1.12
Induced pluripotent stem cells for neural tissue engineering. Biomaterials (2011) 1.11
Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res (2006) 1.11
Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm (2005) 1.11
Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci (2010) 1.10
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10
Androgen deprivation by activating the liver X receptor. Endocrinology (2008) 1.10
Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol (2006) 1.10
Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol (2009) 1.09
Deep sequencing of maize small RNAs reveals a diverse set of microRNA in dry and imbibed seeds. PLoS One (2013) 1.09
Mastering translational medicine: interdisciplinary education for a new generation. Sci Transl Med (2014) 1.08
The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 1.08
A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother (2007) 1.08
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release (2013) 1.08
HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release (2004) 1.08
Engineering bi-layer nanofibrous conduits for peripheral nerve regeneration. Tissue Eng Part C Methods (2011) 1.08
Inhibition of LPS- and CpG DNA-induced TNF-alpha response by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol (2003) 1.08
Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology (2008) 1.07
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07